To the Editor.—
Intralesional administration of bleomycin is a treatment modality not only for superficial malignant lesions, but also for proliferative benign conditions that have been treated unsuccessfully with other methods.1We treated two cases of therapy-resistant leishmaniasis cutis with a single injection of bleomycin. Prior to bleomycin therapy, the patients had been treated with the antimonial stiphophen (Fuadin) for two months in our clinic; however, there was no clinical improvement and smears showed abundant parasites as well (Fig 1).The material used was a 1% solution of bleomycin sulfate in normal saline solution; 1.5 mg of bleomycin was injected intralesionally. Considerable swelling and pain were noted 48 to 72 hours after treatment.The lesions dried out within four weeks and healed both clinically and parasitologically after five weeks of therapy, with only minimal scarring (Fig 2).We suggest that local bleomycin injection was promising in therapy-resistant
Soyuer Ü, Aktaş E. Intralesional Bleomycin Therapy for Leishmaniasis Cutis. Arch Dermatol. 1988;124(10):1571. doi:10.1001/archderm.1988.01670100069022
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: